Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
255
resultados
Última actualización
26/06/2026 [06:53:00]
Resultados 100 a 125 de 255
Resumen de: AU2024383218A1
The present disclosure relates to multimers capable of efficiently activating immune cells, such as T cells. In particular, it relates to multimers comprising at least two different ligands, such as a MHC-peptide and an anti-CD28 antibody, capable of binding to and together activate said immune cell. The disclosure further provides nucleic acid, vectors, and compositions encoding or comprising said multimers, and various methods for their use.
Resumen de: AU2024382784A1
A pharmaceutical composition comprising a nucleic acid construct and the medical use thereof. Specifically, the present invention relates to a lipid nanoparticle comprising a nucleic acid construct represented by formula I, which can achieve highly efficient delivery of a exogenous target gene, allowing the exogenous target gene to be highly efficiently and rapidly expressed in the body. The present invention has the advantages of no gene integration risk and being easy to scale up to an industrial level, is a more ideal treatment approach than naked plasmids, and can be used as a gene therapy drug for a plurality of diseases.
Resumen de: AU2024378001A1
The disclosure relates to compositions and methods for improving pulmonary delivery of therapeutic nucleic acids, e.g., DNA, mRNA, by enhancing transfection efficiency and thus efficacy of the therapeutic nucleic acids, using inhaled, Intranasal, Intratracheal, bronchial instillation and/or topical administration Intratracheal, bronchial instillation and/or topical administration transfection efficiency enhancing agents, including but not limited to 2-mercaptoethane sulfonate or cysteamine.
Resumen de: WO2026124214A1
The present invention relates to the technical field of drug delivery and particularly to a freeze-dried formulation of lipid nanoparticles, a preparation method therefor, and use thereof. In the present invention, suitable freeze-dried formulation formulas, including freeze-drying protectant types and concentrations, buffer types and concentrations, and lipid nanoparticle formulas, are screened to obtain a freeze-dried formulation of lipid nanoparticles that comprises 10%-20% w/v sucrose as a single-component freeze-drying protectant, a 1-20 mM Tris or HEPES buffer as a buffer system, and a specific ionizable lipid. The freeze-dried formulation is simple to prepare and still retains excellent physicochemical properties and in vivo transfection efficiency after reconstitution, demonstrating good prospects in the development and application of nucleic acid drugs.
Resumen de: US20260166173A1
0000 A peptide targeting a BRCA2 protein and an application thereof, and a drug for treating prostate cancer are provided, which relate to the technical field of protein peptides. The amino acid sequence of the peptide is shown in SEQ ID NO: 1. The peptide has strong binding ability with BRCA2 protein, and can deliver the BRCA2 protein into prostate cancer cells, which can effectively inhibit cell proliferation and tumor growth, and has an ability of targeted degradation of BRCA2. Sensitivity of prostate cancer cells to PARP inhibitor can be significantly enhanced by combining the peptide with PARP inhibitor. Thus, the peptide can be used in preparing the drug for treating mCRPC or in preparing a reagent for degrading BRCA2 protein. BRCA2-targeted PROTAC drug can provide a new treatment strategy for prostate cancer, and PARP targeting inhibitor is combined to provide PARP inhibitor synthesis lethality treatment effect for mCRPC patients.
Resumen de: US20260165979A1
0000 Candidate molecules may be constituent components of various lipid nanoparticles. A C-glycoside glycolipid compound of formula (I):
0000
0000 or formula (II):
0000
0000 a lipid nanoparticle comprising the same, or a pharmaceutical composition, particularly a vaccine, which comprises the lipid nanoparticle.
Resumen de: US20260167727A1
0000 The present invention relates to anti-DDR2 antibodies. More specifically, the present invention relates to nano-antibodies binding to DDR2 and various derivatives of the nano-antibodies. The present invention also relates to pharmaceutical compositions comprising these antibodies and derivatives and pharmaceutical uses thereof. The anti-DDR2 nano-antibodies of the present invention have strong binding activity and can be used for diagnosis, prevention and/or treatment of diseases mediated by abnormal DDR2 expression (such as cancer and inflammatory diseases), as well as imaging of cells expressing DDR2, such as biopsy navigation and intraoperative navigation.
Resumen de: US20260165980A1
0000 The present disclosure relates to lymphatic endothelial cell (LEC)-specific lipid nanoparticle comprising a sterol, an ionizable lipid, a PEGylated lipid, and a phospholipid. Also disclosed herein are compositions comprising the LEC-specific lipid nanoparticle and a therapeutic agent. The present disclosure further relates to methods of delivering an agent to a lymphatic system in a subject, comprising administering to the subject an effective amount of the composition of the LEC-specific lipid nanoparticle and therapeutic agent.
Resumen de: US20260165982A1
0000 Provided herein are conjugated lipids and lipid-based particles, such as liposomes and lipid nanoparticles, containing the conjugated lipids. Methods of making the conjugated lipids and the lipid-based particles are described. Conjugated lipids include a lipid conjugated to a cell penetrating peptide. The lipid-based particles may include a payload. Compositions including the lipid-based particles may be administered to a subject.
Resumen de: US20260166162A1
A water-soluble carbon chain substance for regulating transmembrane transport and fluidity of cell membranes, and the preparation and use thereof. The water-soluble carbon chain substance comprises a carbon chain which originally has a certain water solubility, and the structure thereof comprises at least one or more hydrophobic carbon chain parts and one or more hydrophilic groups or residues; and also comprises a high-hydrophilicity complex formed by coupling a hydrophobic carbon chain part to a water-soluble molecule; the water-soluble carbon chain can be used for preventing and treating infection including viruses, bacteria and fungi, anti-ageing, and preventing and reducing the occurrence of neurodegenerative diseases such as Alzheimer's disease; by reducing the non-specific phagocytosis of the nano-drug by cells, the effect of the nano-drug on target lesions is improved.
Resumen de: US20260166149A1
0000 A near-infrared responsive bilirubin composite nanoparticle-loaded periodontal microneedle and a preparation method thereof are provided. A near-infrared responsive bilirubin composite nanoparticle includes a bilirubin-gelatin composite nanoparticle, wherein a surface of the bilirubin-gelatin composite nanoparticle is coated with a macrophage cell membrane and an organic-metal coordination supramolecular network coating in sequence; an outer surface of the near-infrared responsive bilirubin composite nanoparticle is modified with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-folate(polyethylene glycol) (DSPE-PEG-FA); in the bilirubin-gelatin composite nanoparticle, bilirubin and gelatin are covalently bonded via an amide bond; and in the organic-metal coordination supramolecular network coating, an organic ligand is anthocyanin, and a coordinating metal ion is ferric ion.
Resumen de: US20260166148A1
0000 A nanoparticle assembly is disclosed for the treatment and visualization of cancers. The assembly includes a core and two surrounding copolymer layers. The surrounding layers include hydrogel polymers, dextran-iron oxide nanoparticles, and quantum dots having a tail with a photosensitizer and an aptamer targeting cancer cells. Exposure of the assembly to an AC magnetic field creates heat and vibration from magnetostrictive nanobeads in the core. Piezoelectric elements generate electric charges from the vibration that activate fluorescence in the quantum dots, which in turn activate the photosensitizer to generate reactive oxygen species that induce apoptosis in cancer cells. Alternative anticancer mechanisms include thermolytic activation of oxygen independent cytotoxic free radicals from heat caused by magnetostrictive vibration. Thermolysis can also release immunological factors embedded in hydrogel polymers. 2-<18>fluoro-2-deoxyglucose (<18>F-FDG) may be incorporated as a diagnostic tool that can visualize cancer sites with PET-CT. Methods of preparing the nanoparticle assembly are disclosed.
Resumen de: US20260166071A1
0000 Provided herein are compositions and methods of reducing adduct formation.
Resumen de: WO2022081426A1
This disclosure provides peptides which can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
Resumen de: US20260165981A1
The present invention features new lipid-polymer composite particles that are useful for the formulation of bioactive agents for administration to a subject. The nanoparticles include a block copolymer, a lipid, e.g., phospholipid, and a sterol. The formulations of a bioactive agent (e.g., a therapeutic agent, a nutraceutical agent, or a recreational agent) described herein provide for easier loading of lipid-polymer composite particles with higher drug loading capacity, increased stability of the formulations, and lower surface tension of water, which allows for lipid coating and entrapment.
Resumen de: CN115461082A
Provided are gene therapeutic compositions and methods for targeting ATP-binding cassette subfamily A member 4 (ABCA4) or functional fragments thereof in a patient, thereby treating or reducing genetic macular degeneration, including Stargardt's disease or other diseases involving retinal degeneration.
Resumen de: US20260166174A1
The present invention provides a generic platform for delivering molecules with low blood-brain barrier (BBB) penetration into the brain. The nano-delivery system is based on a core nanoparticle which is conjugated through a first polymeric linker to a brain-internalizing transporter moiety, and is further conjugated to a second polymeric linker bound to an active agent selected from a biologically active molecule or a labeling molecule. Further provided is a process for preparation of the nano-delivery system. The present invention further provides pharmaceutical compositions comprising the nano-delivery system and its use in therapeutic and/or diagnostic methods.
Resumen de: US20260165977A1
0000 The present disclosure relates to supraparticles loaded with high levels of payload and having controlled payload release profiles. Such supraparticles may be used in a range of therapeutic applications.
Resumen de: WO2020163705A1
Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that comprise a therapeutic anti-aging agent. Also provided are methods of using such compositions to treat a patient having an age-associated disorder. In particular, exosomes comprising a telomerase-encoding RNA are provided along with methods of their use in treating age-associated disorders.
Resumen de: WO2019210078A1
Aspects of the invention described herein concern targeting of a FOXP3 cDNA, e.g., full-length human-codon optimized, into a FOXP3 locus or a non-FOXP3 locus so as to provide constitutive or regulated FOXP3 expression in a primary human lymphocyte. The compositions and materials described herein provide specificity for CRISPR/Cas-mediated gene regulation of murine, non-human primates or human FOXP3. Guide RNA sequences are used to target the FOXP3, AAVS1, and other candidate loci for CRISPR/Cas-mediated gene regulation, and gene delivery cassettes for HDR based gene-modification are provided. The alternative compositions described herein can be delivered in the form of Ribonucleoprotein (RNP) and may be used to target human and/or non-human primate FOXP3. Reagents are comprised of novel guide RNA sequences and can generate high frequency of on-target cleavage in combination with a Cas protein and novel gene delivery cassettes including FOXP3 cDNA +/-other cis linked gene products.
Resumen de: WO2024254192A2
The present invention provides a method of treating neurodegenerative diseases. The method comprises the step of administering to a subject in need thereof an effective amount of a polymer-flavonoid conjugate, or a nanocomplex having an outer shell comprising one or more polymer-flavonoid conjugates and optionally an inner shell comprising one or more flavonoid oligomer and a drug such as anti-CD3 or anti-CD33 encapsulated within the shells. The present method brings therapeutic effective materials through blood-brain barrier to treat neurodegenerative diseases. The present method is effective to treat neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and Huntington's disease.
Resumen de: EP4759305A1
Provided is a particle in which a core particle is coated with a coating layer and strength of which is ensured. Further provided are an orally disintegrating tablet and the like having improved physical properties (particularly, compactibility, disintegrability, tableting failures, tablet hardness after humidification, and friability after humidification). In a particle according to the present disclosure, a core particle is coated with a coating layer and the coating layer contains cellulose nanofibers. An orally disintegrating tablet according to the present disclosure includes particles containing cellulose nanofibers having an average particle diameter of less than 10 pm.
Resumen de: WO2025035015A1
Compositions and methods for delivery of nucleic acid therapeutics are disclosed herein. In some embodiments, a composition for treating a subject includes a dynamic hydrogel, and a nucleic acid therapeutic encapsulated by the dynamic hydrogel. The dynamic hydrogel can include a polymer and a plurality of nanoparticles. The polymer can be non-covalently crosslinked with the plurality of nanoparticles.
Resumen de: WO2025034870A1
The present application, in certain aspects, pertains to methods and compositions for the treatment of a hormone-dependent cancer (such as an endometrial cancer (e.g., endometrioid endometrial cancer) or hormone-receptor positive breast cancer), using a composition comprising nanoparticles comprising sirolimus and an albumin in combination with an estrogen suppressor (such as letrozole or fulvestrant).
Nº publicación: EP4758186A1 17/06/2026
Solicitante:
UNIV LELAND STANFORD JUNIOR [US]
The Board of Trustees of the Leland Stanford Junior University
Resumen de: WO2025034782A1
The disclosure provides nucleic acid transporters in the form of copolymers derived from lipid carbonate monomers and cationic aminoester monomers prepared using various amino alcohol initiators, including linear and branched amino alcohol initiators, cyclic amino alcohol initiators and imidazole initiators. The compounds are useful for the delivery of nucleic acids to cells in vitro, ex vivo, or in vivo.
BOPI
Sede Electrónica
